3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Lymphoma, Large B-Cell, Diffuse
43
Breast Neoplasms
30
Lymphoma
28
Sarcoma
26
Hodgkin Disease
24
Triple Negative Breast Neoplasms
20
Burkitt Lymphoma
19
Precursor Cell Lymphoblastic Leukemia-Lymphoma
18
Lymphoma, Follicular
16
Neoplasms
15
Ovarian Neoplasms
14
Lymphoma, Non-Hodgkin
13
Lymphoma, B-Cell
13
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
9
Lymphoma, T-Cell, Peripheral
9
Endometrial Neoplasms
9
Neuroblastoma
7
Neoplasm Metastasis
7
Lymphoma, Mantle-Cell
7
Liposarcoma
7
Leukemia
7
Fallopian Tube Neoplasms
7
Recurrence
6
Multiple Myeloma
6
Leiomyosarcoma
6
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
5
Lymphoma, B-Cell, Marginal Zone
5
Leukemia, Lymphocytic, Chronic, B-Cell
5
Inflammatory Breast Neoplasms
5
Histiocytoma, Malignant Fibrous
5
Interventions
Cyclophosphamide
8
ibrutinib
5
fludarabine phosphate
5
fludarabine
5
pirtobrutinib
4
Mesna
4
obinutuzumab
3
acalabrutinib
3
Mycophenolic Acid
3
Melphalan
3
venetoclax
2
Whole-Body Irradiation
2
Tacrolimus
2
Rituximab
2
Peripheral Blood Stem Cell Transplantation
2
Patient Reported Outcome Measures
2
Busulfan
2
Bone Marrow Transplantation
2
ARQ531
2
ricolinostat
1
idelalisib
1
idecabtagene vicleucel
1
Vincristine
1
Stem Cell Transplantation
1
Rabeprazole
1
Prednisone
1
Leukapheresis
1
Itraconazole
1
Filgrastim
1
Doxorubicin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Leukemia, B-Cell
×
Doxorubicin
×
1 year
×
Clear all
NCT06564038
2026-05-14
Soundtrack-E
AstraZeneca
Phase 1/2
Recruiting
408 enrolled